Shanghai Baian Pharmaceutical

Shanghai Baian Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on oncology and autoimmune diseases, where it aims to address significant unmet medical needs through novel mechanisms of action. Its lead clinical candidate, BA-1105, is a highly selective inhibitor of Hematopoietic progenitor kinase 1 (HPK1), designed to enhance the body's anti-tumor immune response. Baian Pharmaceutical utilizes a proprietary drug discovery platform to identify and optimize drug candidates with superior pharmacological profiles. The company is led by a management team with extensive experience in global pharmaceutical R&D and is backed by prominent venture capital investors. By advancing a diverse pipeline of internal programs, Baian Pharmaceutical seeks to provide transformative treatment options for patients worldwide.